Clinical trials: Lymphomas Non-Hodgkin's B-Cell
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma
Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas
This prospective, single-center, open-label study evaluates a short course of CD20×CD3 bispecific antibody-based holding or bridging therapy before CD19-directed CAR T-cell therapy in adults with relapsed or refractory aggressive…
- Trial name
- NCT07883135
- Testing
- Glofitamab, Epcoritamab, Polatuzumab Vedotin
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Overall Survival
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B…
- Trial name
- NCT05392257
- Testing
- Rituximab + zanubrutinib + lenalidomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06313957
- Testing
- LUCAR-20SP cells
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Peking University Cancer Hospital & Institute
Relapsed Non-Hodgkin Lymphoma
Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
The T cell characteristics of 12 patients treated with CD20 CAR-T (LY007 cell injection) were analyzed to study their relationship with CAR-T anti-tumor activity, tumor killing, and in vivo proliferation, and to explore the…
- Trial name
- NCT06049381
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of the study is to examine both efficacy of LBH589 in treating relapsed and refractory DLBCL, and added benefit of combining rituximab with LBH589 in this setting.
- Trial name
- NCT01238692
- Testing
- LBH589, Rituximab
- Where
- 4 sites in Canada
- Volunteers
- 42 people
- Sponsor
- Sarit Assouline
Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+…
- Trial name
- NCT06846463
- Testing
- Zanubrutinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Virginia Commonwealth University
Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.
- Trial name
- NCT02564744
- Testing
- Debio 1562, Rituximab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- Debiopharm International SA
Lymphoma
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005998
- Testing
- carmustine, cyclophosphamide, cytarabine
- Sponsor
- Masonic Cancer Center, University of Minnesota
Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
- Conditions
- Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab
- Trial name
- NCT06871007
- Testing
- Nivolumab
- Where
- 2 sites in Russia
- Volunteers
- 22 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Large B-cell Lymphoma
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in…
- Trial name
- NCT04690192
- Testing
- CNCT19, Gemcitabine Injection, busulfan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non Hodgkin Lymphoma
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects…
- Trial name
- NCT02180711
- Testing
- acalabrutinib, rituximab (IV), Lenalidomide
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Acerta Pharma BV
Diffuse Large B Cell Lymphoma
Imaging Apoptosis for Lymphoma Treatment Response
Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues.
- Trial name
- NCT05048732
- Testing
- 18F-FluorApoTrace
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphoma
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00004916
- Testing
- ifosfamide, paclitaxel, teniposide
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma, Large B-cell, Diffuse
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) combination is considered as the new gold standard for the first-line treatment of elderly patients with diffuse large B-cell lymphoma…
- Trial name
- NCT01181999
- Testing
- rituximab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Chonnam National University Hospital
Diffuse Large B Cell Lymphoma (DLBCL)
Dynamic CtDNA-guided Targeted Therapy in DLBCL
This is a prospective, single-arm, noninferiority trial involving patients with previously untreated CD20-positive DLBCL. The aim of this study is to determine the efficacy and safety of treatment stratified based on ctDNA…
- Trial name
- NCT06748521
- Testing
- R-CHOP + X
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Blood And Marrow Transplantation, Leukemia
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
The goal of this clinical research study is to learn if researchers can successfully and safely give patients who have had a stem cell transplant an infusion of white blood cells (called T-cells) that have been collected from an…
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma
- Trial name
- NCT02274506
- Testing
- Cyclophosphamide, Fludarabine, T-Cell Infusion
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells.
- Trial name
- NCT00019838
- Testing
- 7-hydroxystaurosporine, fludarabine phosphate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma
Biomarker Guided Treatment in DLBCL
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
- Trial name
- NCT04025593
- Testing
- Cyclophosphamide, Rituximab, Doxorubicin
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Ruijin Hospital
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
This study was conducted to evaluate the complete response rate of Ibrutinib + R-CHOP in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
- Trial name
- NCT02670616
- Testing
- Ibrutinib, Rituximab, Cyclophosphamide
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.